Montage Gold, a Canadian mining firm operating in West Africa, is rated 'Buy' with a suggested entry price around $10, below its current ~$14 trading level. The company’s Koné gold project is fully financed, having spent $624 million, with the first gold pour anticipated in late 2026. Competitive all-in sustaining costs (AISC) and significant exploration at Koné, Didievi, and Wende support potential growth into a multi-mine producer. Although the current valuation exceeds the net asset value per share (~$9), a price pullback could offer a better margin of safety and upside from resource expansion.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
